PGENPrecigen, Inc.
$7.82+108% 1Y
$7.82
$3.1052 weeks$8.57
The financials
Precigen, Inc. by the numbers
Precigen, Inc. (PGEN) reported revenue of $55M in Q2 2026 (quarter ended Jun 30, 2026), up 6323% from the same quarter a year earlier. That came with net income of $20M (37% of revenue). For the full year FY2025, revenue was $9.7M (+147% year on year) and net income −$251M. Its largest product in Q2 2026 was Papzimeos at $53M, 97% of the disclosed total, well ahead of Service at 3.1%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $55M | $856K | +6323% |
| Operating income | $23M | −$32M | to a profit |
| Net income | $20M | −$27M | to a profit |
| Diluted EPS | $0.05 | −$0.09 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Papzimeos | $53M | 97% |
| Service | $1.7M | 3.1% |
| Exemplar | $192K | 0.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $55.0M (+136%)
Exemplar grew +368% year on yearService +111% year on year
Segment Latestquarter on quarteryear on year
- Papzimeos$53.1M$53.1Mquarter on quarter +146%year on year n/a+146%n/a
- Service$1.7M$1.7Mquarter on quarter +21%year on year +111%+21%+111%
- Exemplar$192.0K$192.0Kquarter on quarter -19%year on year +368%-19%+368%
On our screens:Most shorted stocks